Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hernia repair cases in New Mexico: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 1,138 | 40% |
| 2020 | 6 | 857 | 43% |
| 2021 | 11 | 924 | 46% |
Open, laparoscopic, and robotic ventral and inguinal hernia repair. Professional codes (what the surgeon bills): CPT 49505, 49650, 49651, 49560, 49561, 49565, 49566, 49570, 49572, 49585, 49587, 49590, 49652, 49653, 49654, 49655, 49656, 49657, 49591, 49592, 49593, 49594, 49595, 49596, 49613, 49614, 49615, 49616, 49617, 49618, 49621, 49622; the hospital bills MS-DRG 353, 354, 355.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 96% of the cases CMS names in New Mexico; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 233 | 17,286−1.1%/yr | −1.1%/yr | 5.5 | 15% | 19,300 in 2030+1.8%/yr |
| Arizona | 84 | 5,543 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cholecystectomy & appendectomy | 9 | 736−6.4%/yr | −6.4%/yr | 3.30.9× | 0% | 870 in 2030+2.8%/yr |
| Colorectal resection |
Hernia repair in every state, and its device makers · Every procedure market in New Mexico · Every state · Compare with California
| ≈ 960 |
| – |
| 2026 est. | ≈ 950 | – |
| 2022 | 11 | 1,047 | 50% |
| 2023 | 11 | 982 | 53% |
| 2024 | 11 | 986 | 54% |
| 2025 from claims | – | 956 773–1,122 | 54% |
| 2026 forecast | – | 953 746–1,197 | 55% |
| 2027 forecast | – | 958 711–1,267 | 55% |
| 2028 forecast | – | 964 682–1,330 | 56% |
| 2029 forecast | – | 969 659–1,390 | 56% |
| 2030 forecast | – | 975 639–1,447 | 56% |
In 2025, 1% inpatient hospital, 97% hospital outpatient, 1% surgery center.
| −0.6%/yr |
| 7.9 |
| 12% |
| 6,180 in 2030+1.8%/yr |
| Washington | 50 | 4,184−4.3%/yr | −4.3%/yr | 5.8 | 11% | 4,250 in 2030+0.3%/yr |
| Colorado | 52 | 3,413−0.2%/yr | −0.2%/yr | 7.4 | 11% | 3,950 in 2030+2.5%/yr |
| Oregon | 23 | 2,486−2.6%/yr | −2.6%/yr | 6.3 | 10% | 3,210 in 2030+4.4%/yr |
| Utah | 25 | 1,792+0.1%/yr | +0.1%/yr | 8.7 | 7% | 1,820 in 2030+0.3%/yr |
| Nevada | 24 | 1,609−1.2%/yr | −1.2%/yr | 6.0 | 0% | 1,850 in 2030+2.4%/yr |
| Idaho | 14 | 1,085−3%/yr | −3%/yr | 5.6 | 1% | 1,430 in 2030+4.7%/yr |
| Montana | 14 | 967−2.5%/yr | −2.5%/yr | 5.3 | 2% | 1,050 in 2030+1.3%/yr |
| Alaska | 8 | 607+4.7%/yr | +4.7%/yr | 5.1 | 8% | 750 in 2030+3.5%/yr |
| Wyoming | 5 | 507+0.6%/yr | +0.6%/yr | 4.8 | 0% | 660 in 2030+4.6%/yr |
| Hawaii | 2 | 372−1.1%/yr | −1.1%/yr | 3.1 | 4% | 390 in 2030+1%/yr |
| 0 |
| 182−11%/yr |
| −11%/yr |
| 0.80.6× |
| 0% |
| 170 in 2030−1.5%/yr |
| Antireflux & hiatal hernia surgery | 1 | 129−1.8%/yr | −1.8%/yr | 0.60.8× | 0% | 130 in 2030+0.3%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
W L Gore & Associates leads with 88% of company spending on these surgeons in 2025, level with 2024.
In 2025, 7 companies reported engagement with New Mexico’s surgeons worth $15K in consulting, speaking, meals and travel tied to these products, about $1,326 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.